Sobycor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sobycor

Property Description
Active ingredient Bisoprolol fumarate
Form Film-coated tablet
Pharmacological class Beta-blocker (Cardioselective beta1 Antagonist)
General purpose Cardiovascular stabilization, Antihypertensive
Origin Synthetic compound

What Type of Medicine is Sobycor?

Sobycor is a prescription-only medication that belongs to the pharmacological class of beta-blockers, specifically defined as a cardioselective beta1 adrenergic antagonist. The core active ingredient is bisoprolol fumarate, a potent synthetic compound. This specialized classification means the drug's action is principally directed toward the beta1 receptors in the heart. This identity establishes Sobycor as a foundational antihypertensive agent and an anti-arrhythmia drug. Its high-level general purpose is to provide controlled support for the cardiovascular system.

The Composition and Form of Sobycor

The active agent within Sobycor is bisoprolol fumarate, a single-ingredient product supplied as a racemic mixture and formulated into a characteristic film-coated tablet for oral administration. This particular formulation features a relatively long half-life, typically ranging from 9 to 12 hours. This long half-life is a differentiating compositional feature, as it allows the drug to be used in a consistent once-daily dosing regimen, providing stable therapeutic coverage. The drug is used for managing cardiac conditions, including chronic stable angina and hypertension.

How Sobycor Contributes to Cardiovascular Stability

Sobycor's mechanism of effect operates as a sympatholytic agent, which means it selectively blocks the excitatory signals that the sympathetic nervous system sends to the heart. It achieves this through selective beta1 adrenergic receptor blockade, competitively inhibiting the stimulating effects of natural stress hormones, known as catecholamines. The general benefit of this action is a functional reduction in the heart's overall workload and a decreased demand for oxygen by the heart muscle. This therapeutic effect contributes directly to the maintenance of stable blood pressure and a more regulated heart rhythm.

Regulatory References

  1. NIH: Beta-Blockers

What side effects are possible with Sobycor?

Possible Side Effects and Safety Information

Sobycor (bisoprolol fumarate) is associated with a defined safety profile that is classified according to the frequency of adverse reactions documented in official regulatory labeling. These classifications establish the likelihood and nature of possible effects across several physiological systems.


Frequency-Classified Adverse Reactions

The following are examples of adverse reactions grouped by System Organ Class and official frequency tiers:

Frequency Tier System Organ Class Example Adverse Reaction
Very Common (ge1/10) Cardiac disorders Bradycardia (slowed heart rate)
Common (ge1/100) Nervous system disorders Dizziness, Headache
Vascular disorders Feeling of coldness or numbness in the extremities
Gastrointestinal disorders Nausea, Vomiting, Diarrhoea, Constipation
Uncommon (ge1/1,000) Cardiac disorders Worsening of pre-existing heart failure
Rare (ge1/10,000) Skin disorders Hypersensitivity reactions (rash, itching)

Serious Safety Considerations and Limitations

The safety profile includes restrictions and warnings for specific clinical situations. The most critical safety note documented is the risk of abrupt discontinuation. For patients with ischaemic heart disease, stopping treatment suddenly may lead to a clinically significant exacerbation of angina, myocardial infarction, or ventricular arrhythmia.

Safety constraints are also specified for certain populations. In individuals with severe renal or hepatic impairment, the dose is officially limited. For patients with diabetes mellitus, the medication may mask certain symptoms of hypoglycemia. Furthermore, use is not recommended in the paediatric population due to a lack of available data in children.

Some common effects, such as headache and dizziness, are typically transient and may resolve within the first one to two weeks of therapy. Transient worsening of heart failure may also occur during the initial dose-titration period.

Overdose and Emergency Response

Sobycor Overdose and When to Seek Help

The regulatory profile for Sobycor (bisoprolol fumarate) overdose details serious clinical manifestations linked to profound beta-blockade. Officially documented symptoms primarily affect the cardiovascular system and include bradycardia (abnormally slow heart rate), severe hypotension (low blood pressure), and acute congestive heart failure. Respiratory system effects may include bronchospasm, while systemic manifestations can lead to central nervous system depression, evidenced by drowsiness, confusion, and potential progression to convulsions or coma.

Immediate and urgent medical action is mandated for all suspected overdose cases. Official guidance requires the immediate cessation of bisoprolol fumarate therapy and instructs patients to seek immediate medical attention for any signs of overdose. Due to the risk of life-threatening outcomes, such as shock, urgent medical assistance and hospital monitoring are required.

Regulatory information confirms that no specific antidote is known for bisoprolol overdose. Management is strictly supportive and symptomatic, with procedural interventions guided by the presenting clinical signs. These procedures may include continuous vital sign monitoring and the use of specific agents, such as sympathomimetic agents or glucagon, to manage cardiac depression. Furthermore, hypoglycemia is noted as a specific, common presentation in children experiencing bisoprolol overdose.

Therapeutic Uses of Sobycor

Sobycor (bisoprolol fumarate) is a foundational medication used for the long-term management of several significant cardiovascular conditions and supports general well-being during symptomatic phases of the condition. It is applied across domains where additional symptomatic support is needed, such as in the therapeutic management of mild to moderate high blood pressure (hypertension), chronic stable angina pectoris (chest discomfort), and certain types of chronic heart failure (reduced ejection fraction).

In these therapeutic contexts, Sobycor may assist with managing the intensity of symptoms related to physical discomfort, and may help patients cope more steadily with symptom fluctuations related to heightened physiological activity. Used as a cornerstone of standard therapy, the medication provides support that helps ease the overall symptom burden for individuals managing chronic heart disease.

Quick Fact: Relief for Heightened Symptoms

Sobycor is relevant when supportive symptom management is appropriate for conditions marked by increased physiological stress, often applied in clinical settings that involve chronic or disruptive symptom patterns that interfere with daily functioning. It helps improve day-to-day comfort during symptomatic periods and may assist with maintaining functional stability.

Eligibility and Restrictions for Use

Sobycor (bisoprolol fumarate) is approved for use in adults for conditions such as stable chronic heart failure, hypertension, and chronic stable angina pectoris.

The medicine is strictly contraindicated (must not be used) if you have:

  • Acute heart failure or decompensation requiring intravenous (i.v.) inotropic therapy.
  • Cardiogenic shock.
  • Second or third degree atrioventricular (AV) block (without a pacemaker), sick sinus syndrome, or sinoatrial block.
  • Symptomatic bradycardia (very slow heart rate) or symptomatic hypotension (very low blood pressure).
  • Severe bronchial asthma or severe chronic obstructive pulmonary disease (COPD).
  • Severe peripheral arterial occlusive disease or Raynaud's syndrome.
  • Untreated phaeochromocytoma (a tumor of the adrenal gland).
  • Metabolic acidosis or known hypersensitivity to the drug or its excipients.

Use is not recommended or requires special consideration for several groups. The drug cannot be recommended for children and adolescents (under 12 years) due to a lack of safety and efficacy data. It is not recommended during pregnancy or lactation. Special caution and possible dose adjustments are required for patients with severe hepatic (liver) or renal (kidney) impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sobycor (bisoprolol fumarate) has officially documented interaction patterns primarily involving pharmacodynamic synergy and altered drug clearance, as detailed in regulatory documents.

Interaction Classifications

Co-administration with other beta-blocking agents is contraindicated. Use is generally not recommended with specific Calcium Channel Blockers, such as Verapamil and Diltiazem, due to the risk of additive negative effects on heart contractility and conduction.

Pharmacodynamic Interactions

  • Digitalis glycosides and certain antiarrhythmic drugs (Class I and III) may potentiate the effect on atrioventricular conduction time, increasing the risk of bradycardia.
  • Catecholamine-depleting drugs (e.g., Reserpine) may produce an excessive reduction of sympathetic activity due to additive beta-adrenergic blocking action.

Pharmacokinetic Clearance Modification

  • Rifampin co-administration increases the metabolic clearance of bisoprolol, resulting in a shortened elimination half-life, which reflects reduced exposure.
  • No clinically relevant interaction is documented with Cimetidine.

Timing-Based Constraints

  • When discontinuing concurrent therapy with Clonidine, Sobycor must be discontinued for several days before the withdrawal of Clonidine.

Substance Interactions

  • Alcohol can lead to an additive blood pressure-lowering effect, which increases the risk of hypotension.

Mechanism of Action

Sobycor's mechanism of action involves the engagement of regulatory pathways in the cardiovascular system, resulting in specific alterations to cardiac and hormonal function.

Selective Suppression of Cardiac beta1 Adrenergic Signals

The primary action of bisoprolol fumarate is its role as a competitive antagonist that selectively blocks beta1 adrenergic receptors in the heart. These receptors are located in the myocardium and the heart's electrical conduction system. The drug binds reversibly, preventing the stimulating effects of catecholamines (norepinephrine and epinephrine) from activating the receptors. By interrupting this signal cascade, the drug dampens the activation of the mathbfGs protein pathway, ultimately limiting the calcium influx into heart muscle cells. This core molecular action results in a dual physiological consequence: a reduction in both the heart rate (negative chronotropy) and the force of contraction (negative inotropy).

Modulation of the Renin-Angiotensin-Aldosterone System (RAAS)

This secondary domain involves the mechanism by which Sobycor affects hormonal regulation originating in the kidneys. By blocking beta1 receptors on the juxtaglomerular cells, the drug reduces the release of the enzyme renin, which is the initiator of the powerful RAAS pathway. This attenuation limits the downstream production of hormones that typically cause widespread blood vessel narrowing and fluid retention. This attenuation results in a reduction of circulating vasoconstrictors and volume-retaining hormones.

Dosage and Administration Information

How to Use Sobycor: Official Administration Guidelines

Sobycor (bisoprolol fumarate) is an oral medication administered exclusively as a film-coated tablet, with official instructions governing its use, frequency, and dose ranges. The tablet must be swallowed whole with a liquid and should not be crushed or chewed. Administration is typically conducted once daily in the morning and can be taken with or without food.


Official Dosing Protocols

Official prescribing information outlines different dosing schedules based on the managed condition:

  • Hypertension and Chronic Stable Angina: Therapy generally begins with a starting dose of 5 mg once daily. The standard maintenance range is 5 mg to 10 mg, with a maximum recommended dose of 20 mg once daily.
  • Chronic Heart Failure (CHF): Treatment initiation requires a very low starting dose of 1.25 mg once daily. The dose must then be increased gradually through a defined titration schedule, often involving dose increases at weekly intervals, until a maximum target dose of 10 mg once daily is achieved.

Procedural and Population Requirements

Official guidelines define specific procedural constraints and population-based rules for use. For individuals with significant renal or hepatic impairment, the initial daily dose is recommended to be limited to 2.5 mg. Furthermore, Sobycor is a long-term medication that must be discontinued gradually. The official protocol requires a stepwise dose reduction (tapering) over a period, such as one week, to avoid rebound effects upon cessation. If a daily dose is missed, it should be taken as soon as it is remembered on that day, but a double dose should not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sobycor (Bisoprolol Fumarate)


Evidence for Use in Chronic Heart Failure

Research explored the use of bisoprolol fumarate in the context of Chronic Heart Failure with Reduced Ejection Fraction (HFrEF). The evidence foundation includes large-scale, international Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies involved patients with stable heart failure who were already receiving other concurrent study treatments. Research examined outcomes related to all-cause mortality, the frequency of heart failure-related hospitalization, and changes in the heart's pumping ability. Findings describe patterns observed as key cardiovascular outcomes were monitored over the long term.

Evidence for Use in High Blood Pressure (Hypertension)

Research examined the use of bisoprolol fumarate in numerous placebo-controlled and active-comparator RCTs focused on adults with mild to moderate high blood pressure. Studies monitored change from baseline in both systolic and diastolic blood pressure readings, alongside effects on the resting heart rate. The available short-term trials consistently report measurements documenting the general change in blood pressure and heart rate. However, comparative evidence is limited regarding long-term cardiovascular outcomes when compared against some other blood pressure medications.

Evidence for Use in Chronic Stable Angina Pectoris

Bisoprolol fumarate was studied for its use in conditions involving periods of heightened symptoms of chronic stable angina pectoris (chest discomfort). Studies monitored physiological strain, measuring outcomes such as changes in exercise tolerance and the reported frequency of anginal attacks over defined time intervals. Research includes controlled studies, but the evidence related to long-term, definitive cardiovascular outcomes is less established.


What Remains to be Understood

Research, while extensive for certain indications, contains gaps where more data are needed. The certainty remains low regarding the long-term effects on some major cardiovascular outcomes for indications other than heart failure, as many studies primarily tracked symptomatic evaluation over short intervals. Data for specific patient groups, such as those with severe concomitant respiratory or organ impairment, is limited. The applicability of trial results to the entire spectrum of patients seen in daily practice is not always certain.

Frequently Asked Questions (FAQ)

Common questions about Sobycor (FAQ)

Q: How soon after starting Sobycor might a patient expect to notice an effect?

Official labeling indicates that the initial effects of Sobycor on heart rate typically start within a few hours of the first dose. For high blood pressure treatment, a notable blood pressure reduction is often observed within one week. However, the full therapeutic effect of the medication usually develops over a period of two to six weeks.

Q: Is it normal to feel a temporary change in energy or fatigue when beginning Sobycor?

Official product information states that fatigue (feeling overly tired) is a common side effect. It is noted that these effects are typically mild and temporary. They may lessen or resolve completely over the first few weeks as the patient's body adjusts to the medication.

Q: Does Sobycor have any described interactions with over-the-counter pain relievers?

According to official regulatory documents, certain over-the-counter pain relievers can interact with Sobycor. Specifically, NSAIDs (a class of medicines like ibuprofen) may reduce the medication's effectiveness in lowering blood pressure.

Q: What safety information is available for Sobycor use in older adults?

Clinical studies examining Sobycor use in older adults reported that this patient group experienced similar blood pressure reductions when compared to younger adults. Official information indicates that dose adjustment is not generally necessary based solely on age.

Q: What are the known potential effects of Sobycor on sleep patterns?

According to official patient information, difficulty falling asleep or staying asleep (insomnia) and other sleep disorders are reported as an uncommon side effect. This type of effect is categorized under the medication's list of possible adverse reactions.

Q: What steps should be taken if a user experiences a minor side effect from Sobycor?

Official patient counseling information advises that if side effects are experienced, particularly if they are severe or do not go away, the patient should tell their doctor or healthcare provider.

Q: Does Sobycor interact with common cold or flu medications?

Regulatory documents contain a warning that some over-the-counter cough, cold, or allergy medications may interact with Sobycor. This is because some of these products can contain ingredients, such as decongestants, that may increase blood pressure. Official counseling information advises discussion with a healthcare provider regarding their use.

Q: Is it possible for Sobycor to cause blurry vision?

Official safety information lists blurred vision as a potential side effect. It is also noted that blurred vision can be a sign that the medication has caused a drop in blood pressure that is too low (hypotension).

Q: Can Sobycor affect a person's ability to operate machinery or drive?

According to official warnings, Sobycor may cause side effects such as dizziness, drowsiness, or fatigue. Due to the risk of temporarily impaired coordination or judgment, official warnings advise against driving or operating machinery until the patient knows how the medication affects them.

Q: Are there any reported mental health effects linked to Sobycor?

Official labeling includes reports of some Central Nervous System (CNS) effects. Depression is listed as an uncommon side effect. Other reported effects include anxiety, nervousness, and nightmares.

Q: Is Sobycor used to treat symptoms, or does it target an underlying process?

Regulatory documents describe Sobycor as targeting an underlying process within the body. Its core action involves blocking the effects of stress hormones on the heart and helping to regulate the release of a hormone called renin from the kidneys. This molecular action ultimately contributes to cardiovascular stability.

Q: Does taking Sobycor impact kidney function?

Official information confirms that Sobycor is cleared from the body through both the liver and the kidneys. For individuals who have existing severe kidney impairment, regulatory guidelines specify a lower starting dose limit. This is because severe kidney issues can affect how quickly the drug is removed from the body.

Q: Does Sobycor have different effects on men versus women?

Clinical studies noted that blood pressure reductions were generally similar for both men and women. However, the regulatory documents do report sexual side effects as a possible adverse reaction in the drug's safety profile.

Q: Can Sobycor be taken alongside vitamins or mineral supplements?

Official patient counseling information emphasizes the importance of informing the healthcare provider about all prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products taken. This is because these products may cause an interaction or potentially reduce the medicine's effectiveness.

How should Sobycor be stored and disposed of?

How to Store and Dispose of Sobycor

Official regulatory labeling dictates specific storage and disposal requirements for Sobycor (bisoprolol fumarate) tablets to maintain product quality and ensure safety.


Storage Requirements

Storage conditions are dependent on packaging. For certain container types, the product must be stored below 25°C (77°F), particularly after the first opening of an HDPE bottle. It is mandatory to store the tablets in the original package to ensure protection from light. For the HDPE bottle, the drug has a defined in-use shelf life of 6 months after opening. Additionally, the medicine must be kept out of the sight and reach of children.


Disposal Instructions

Any unused or expired Sobycor must be discarded appropriately. Disposal of the medicinal product or waste material must be carried out in accordance with local requirements. This instruction prevents the improper disposal of medicine into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sobycor found in:

A-Z Index: